Kestra Medical Technologies, Ltd. Common Stock (KMTS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kestra Medical Technologies, Ltd. Common Stock stock (KMTS) is currently trading at $20.58. Kestra Medical Technologies, Ltd. Common Stock PS ratio (Price-to-Sales) is 13.32. Analyst consensus price target for KMTS is $28.71. WallStSmart rates KMTS as Sell.
- KMTS PE ratio analysis and historical PE chart
- KMTS PS ratio (Price-to-Sales) history and trend
- KMTS intrinsic value — DCF, Graham Number, EPV models
- KMTS stock price prediction 2025 2026 2027 2028 2029 2030
- KMTS fair value vs current price
- KMTS insider transactions and insider buying
- Is KMTS undervalued or overvalued?
- Kestra Medical Technologies, Ltd. Common Stock financial analysis — revenue, earnings, cash flow
- KMTS Piotroski F-Score and Altman Z-Score
- KMTS analyst price target and Smart Rating
Kestra Medical Technologies,
📊 No data available
Try selecting a different time range
Smart Analysis
Kestra Medical Technologies, Ltd. Common Stock (KMTS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Kestra Medical Technologies, Ltd. Common Stock (KMTS) Key Strengths (2)
Revenue surging 62.70% year-over-year
98.29% of shares held by major funds and institutions
Supporting Valuation Data
Kestra Medical Technologies, Ltd. Common Stock (KMTS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 13.3x annual revenue
Premium pricing at 3.9x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Kestra Medical Technologies, Ltd. Common Stock (KMTS) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 62.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (13.32), Price/Book (3.87) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -92.60%, Operating Margin at -141.60%, Profit Margin at -173.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -92.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 62.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KMTS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KMTS's Price-to-Sales ratio of 13.32x trades 43% below its historical average of 23.38x (0th percentile). The current valuation is 74% below its historical high of 50.85x set in Apr 2025, and 0% above its historical low of 13.32x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~49.2x as trailing revenue scaled faster than the stock price.
Compare KMTS with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Kestra Medical Technologies, Ltd. Common Stock (KMTS) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Kestra Medical Technologies, Ltd. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 84M with 63% growth year-over-year. The company is currently unprofitable, posting a -173.0% profit margin.
Key Findings
Revenue growing at 63% YoY, reaching 84M. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 175M in cash.
The company is unprofitable with a -173.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -28M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Kestra Medical Technologies, Ltd. Common Stock maintain 63%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Kestra Medical Technologies, Ltd. Common Stock.
Bottom Line
Kestra Medical Technologies, Ltd. Common Stock is a high-conviction growth story with revenue accelerating at 63% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -173.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kestra Medical Technologies, Ltd. Common Stock(KMTS)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.